

quickly (19 vs 48 days, log-rank test; $p=0.01$). In patients with uMCP-1 >1354 pg/mg-Cr, they also died more quickly, but with no significance (25 vs 48 days, log-rank test; $p=0.08$).
CONCLUSION: Urinary biomarkers NGAL and MCP-1 quantified at hospital admission were associated with poor outcomes, mostly with needed of invasive respiratory support in ICU. Prediction cut-off values for invasive respiratory support was useful to determine the survival prognosis.

MO365

URINARY BIOMARKERS AND POOR OUTCOMES IN PATIENTS WITH COVID-19 ADMITTED TO A REFERENCE HOSPITAL IN NORTHEAST BRAZIL

Gdayllon Cavalcante Meneses¹, Gabriela Freire Bezerra¹, Lana Andrade Lucena Lima¹, Izabel Cristina Justino Bandeira¹, Nicole Coelho Lopes¹, Márcia Maria Pinheiro Dantas², Sandra Maria Brasileiro Mota², Polianna Lemos Moura Moreira Albuquerque^{2,3}, Alice Maria Costa Martins¹, Elizabeth De Francesco Daher¹, Geraldo Bezerra da Silva Junior³

¹Federal University of Ceará, Fortaleza, Brazil, ²Toxicological Assistance Center, Instituto Dr Jose Frota Hospital, Fortaleza, Brazil and ³University of Fortaleza, Fortaleza, Brazil

BACKGROUND AND AIMS: Kidney biomarkers improve early and specific AKI detection and also poor outcomes in different clinical contexts. Kidney disease is an important risk factor for poor outcomes in COVID-19. The aim of this study was to evaluate association of early levels of kidney biomarkers with poor outcomes in hospitalized patients with COVID-19.

METHOD: This is a prospective study conducted at the Instituto Dr. Jose Frota Hospital, an important public reference hospital for COVID-19 in northeast Brazil. Medical records with clinical, epidemiologic, laboratory and outcomes were collected. The urinary NGAL, KIM-1, MCP-1 and nephrin were the kidney biomarkers quantified at hospital admission. ELISA assays were used for analysis and biomarkers urinary concentrations were adjusted for urinary creatinine. Data were expressed as mean \pm standard deviation or median.

RESULTS: A total of 69 patients collected urine and were included in this study. Male gender was predominant (65%) and mean age was 56 ± 19 years. Regarding outcomes, the group had 62% of death, 92% of ICU admission and 65% of invasive respiratory support in ICU. Urinary NGAL and MCP-1 were significantly elevated in patients that needed invasive respiratory support in comparison with non-invasive support: uNGAL (median=104 [IQR=74-153] vs 71 [31-79] ng/mg-Cr, $p=0.013$), and uMCP-1 (3055 [1127-5008] vs 1315 [574-2127] pg/mg-Cr, $p=0.027$). Urinary nephrin and KIM-1 was also elevated, however with no statistical significance. Moreover, all urinary biomarkers were higher in ICU admission group and death group, but with $p>0.05$. In ROC curve analysis for prediction of invasive respiratory support, uNGAL had AUC=0.696 (0.565-0.827), $p=0.012$ and cut-off=78 ng/mg-Cr; uMCP-1 had AUC=0.676 (0.539-0.813), $p=0.023$ and cut-off=1354 pg/mg-Cr. In survival analysis, patients with uNGAL >78 ng/mg-Cr had worse prognosis and died more